Chemotherapy remains the only practicable tool to control falciparum malaria in sub-
Saharan Africa, where> 90% of the world's burden of malaria mortality and morbidity occurs …

Introduction: Plasmodium falciparum, the deadly agent of malaria, is notorious for its
capacity to develop drug resistance. Treatment failures of artemisinin therapy regimens …

The emergence of multidrug resistance (MDR) plays a crucial role in the failure of treatments
of tumors and infectious diseases and in the control of plant pathogens, weeds and food …

In plasmodia, the dihydrofolate reductase (DHFR) enzyme is the target of the pyrimethamine
component of sulfadoxine-pyrimethamine (S/P). Plasmodium vivax infections are not treated …

OBJECTIVE: To evaluate the therapeutic efficacy of sulfadoxine-pyrimethamine,
amodiaquine, and the sulfadoxine-pyrimethamine-amodiaquine combination for the …

Mutations at five positions in the Plasmodium falciparum multidrug-resistance gene 1
(pfmdr1), initially thought to confer resistance to chloroquine, have been associated with in …

Increasing resistance, recrudescences, and treatment failure have led to the replacement of
chloroquine with the combination of pyrimethamine (PYR) and sulfadoxine (SDX) as the first …

As predicted based on structural considerations, we show results indicating that the member
of the major facilitator superfamily encoded by Saccharomyces cerevisiae open reading …

We have expressed dhfr alleles of Plasmodium falciparum in the budding yeast,
Saccharomyces cerevisiae, and used this yeast model to identify single amino acid …

Inhibitors of dihydrofolate reductase (DHFR) have been a mainstay of chemotherapy of
falciparum malaria for> 50 years. Unfortunately, point mutations in DHFR are the major …